Date: 2014-09-18
Type of information: Development agreement
Compound: CV9202
Company: Boehringer Ingelheim (Germany) CureVac (Germany)
Therapeutic area: Cancer - Oncology
Type agreement: development licensing
Action mechanism: immunotherapy product. CV9202 is a cancer immunotherapy based on CureVac's RNA technology (RNActive®). CV9202 is a combination of mRNA molecules coding for six antigens overexpressed in lung cancer, designed to induce an immune response against the tumor.
Disease: lung cancer
Details: * On September 18, 2014, Boehringer Ingelheim and CureVac announced an exclusive global license and development collaboration. The new collaboration focuses on CureVac's CV9202, a novel investigational therapeutic mRNA vaccine in early clinical development for the treatment of lung cancer. Boehringer Ingelheim will start clinical investigation of CV9202 in at least two different lung cancer settings, in combination with afatinib in patients with advanced or metastatic epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC) and in combination with chemo-radiation therapy in patients with unresectable stage III NSCLC.
This new agreement is part of Boehringer Ingelheim's long-term commitment to delivering tomorrow's cancer therapies through the discovery of novel treatment options with high therapeutic value for patients. The company's oncology portfolio includes afatinib, a once-daily kinase inhibitor that irreversibly binds and inhibits ErbB1, ErbB2 and ErbB4 receptors and is approved in a number of markets including the EU and US. In the US, afatinib is marketed as Gilotrif® for the first-line treatment of common types of EGFR-mutation positive metastatic NSCLC (Del 19 or L858R).
Financial terms: CureVac receives €35 million (approximately $45 million). Further, CureVac can achieve milestone payments of up to € 430 million (approximately $556 million) and royalties on sales.
Latest news:
